Table 1.
Characteristics of patients with cervical adenocarcinoma or squamous cell carcinoma who received definitive concurrent chemoradiotherapy
| Total (N = 3258) | SCC (N = 2927) | Adenocarcinoma (N = 331) | P value | ||
|---|---|---|---|---|---|
|
|
|
|
|||
| n (%) | n (%) | n (%) | |||
| Age, years | Mean (SD) | 57.6 (12.0) | 57.9 (12.0) | 55.3 (11.6) | .0001 |
| Median (min, max) | 57.0 (25, 91) | 57.0 (25, 91) | 54.0 (28, 88) | ||
| Age group | 20-49 | 821 (25.2) | 711 (24.3) | 110 (33.2) | .0013 |
| 50-59 | 1125 (34.5) | 1013 (34.6) | 112 (33.8) | ||
| 60-69 | 685 (21.0) | 622 (21.3) | 63 (19.0) | ||
| ≥ 70 | 627 (19.2) | 581 (19.8) | 46 (13.9) | ||
| Year of diagnosis | 2007-2009 | 1048 (32.2) | 944 (32.3) | 104 (31.4) | .1124 |
| 2010-2012 | 1058 (32.5) | 964 (32.9) | 94 (28.4) | ||
| 2013-2015 | 1152 (35.4) | 1019 (34.8) | 133 (40.2) | ||
| FIGO stage | IB2 | 506 (15.5) | 438 (15.0) | 68 (20.5) | .0154 |
| II | 1575 (48.3) | 1426 (48.7) | 149 (45.0) | ||
| III | 764 (23.4) | 699 (23.9) | 65 (19.6) | ||
| IVA | 413 (12.7) | 364 (12.4) | 49 (14.8) | ||
| EBRT cumulative dose, Gy | Mean (SD) | 51.8 (18.7) | 51.9 (18.8) | 50.8 (17.0) | .6814 |
| Median (Q1, Q3) | 52 (38, 60) | 52 (38, 60) | 52 (37, 60) | ||
| EBRT cumulative dose | < 50 Gy | 1404 (43.1) | 1262 (43.1) | 142 (42.9) | .9402 |
| ≥ 50 Gy | 1854 (56.9) | 1665 (56.9) | 189 (57.1) | ||
| Platinum cumulative dose, mg | Mean (SD) | 558.3 (480.1) | 555.3 (467.6) | 584.2 (578.8) | .8719 |
| Median (IQR, Q1, Q3) | 500 (300, 600) | 490 (300, 600) | 500 (300, 600) | ||
| Platinum cumulative dose | < 500 mg | 1628 (50.0) | 1470 (50.2) | 158 (47.7) | .3909 |
| ≥ 500 mg | 1630 (50.0) | 1457 (49.8) | 173 (52.3) | ||
| IC Brachytherapy | No | 554 (17.0) | 485 (16.6) | 69 (20.8) | .0497 |
| Yes | 2704 (83.0) | 2442 (83.4) | 262 (79.2) | ||
| IC Brachytherapy dose, cGy | Mean (SD) | 2390.6 (675.8) | 2405.0 (672.5) | 2362.9 (692.9) | .1009 |
| Median (IQR, Q1, Q3) | 2500 (2000, 3000) | 2500 (2000, 3000) | 2500 (2000, 3000) | ||
| IC Brachytherapy dose | No IC Brachytherapy | 554 (17.0) | 485 (16.6) | 69 (20.8) | .1124 |
| < 2500 cGy | 1119 (34.3) | 1005 (34.3) | 114 (34.4) | ||
| ≥ 2500 cGy | 1585 (48.6) | 1437 (49.1) | 148 (44.7) | ||
| CCI Scores | Mean (SD) | 0.4 (0.9) | 0.4 (0.9) | 0.4 (0.9) | .4343 |
| 0 | 2464 (75.6) | 2220 (75.8) | 244 (73.7) | .6608 | |
| 1 | 481 (14.8) | 427 (14.6) | 54 (16.3) | ||
| ≥ 2 | 313 (9.6) | 280 (9.6) | 33 (10.0) | ||
| Income | < 18,000 NTD | 931 (28.6) | 847 (28.9) | 84 (25.4) | .0275 |
| 18,000-22,500 NTD | 1067 (32.8) | 972 (33.2) | 95 (28.7) | ||
| 22,500-30,000 NTD | 465 (14.3) | 414 (14.1) | 51 (15.4) | ||
| ≥ 30,000 NTD | 795 (24.4) | 694 (23.7) | 101 (30.5) | ||
| Hospital type | Medical center | 2391 (73.4) | 2142 (73.2) | 249 (75.2) | .4247 |
| others | 867 (26.6) | 785 (26.8) | 82 (24.8) | ||
| Hospital location | North | 1629 (50.0) | 1476 (50.4) | 153 (46.2) | .0792 |
| Middle | 710 (21.8) | 622 (21.3) | 88 (26.6) | ||
| South/East | 919 (28.2) | 829 (28.3) | 90 (27.2) | ||
| Mean of follow-up time, months (SD) | 54.6 (35.5) | 56.2 (35.4) | 41.1 (33.6) | ||
| Death | 1264 (38.8) | 1081 (36.9) | 183 (55.3) | < .0001 | |
| Local recurrence | 422 (13.0) | 364 (12.4) | 58 (17.5) | < .0001 | |
| Distant metastasis | 503 (15.4) | 428 (14.6) | 75 (22.7) | < .0001 | |
Gy, gray; cGy, centigray; SCC, squamous cell carcinoma; ADC, adenocarcinoma; FIGO, International Federation of Gynecology and Obstetrics; EBRT, external beam radiotherapy; CCI, Charlson comorbidity index; mg, milligrams; SD, standard deviation; IQR, interquartile range; NTD, New Taiwan dollar; IC, intracavitary.